WO2006022954A3 - Benzo-urees a activite antidiabetique - Google Patents

Benzo-urees a activite antidiabetique Download PDF

Info

Publication number
WO2006022954A3
WO2006022954A3 PCT/US2005/018721 US2005018721W WO2006022954A3 WO 2006022954 A3 WO2006022954 A3 WO 2006022954A3 US 2005018721 W US2005018721 W US 2005018721W WO 2006022954 A3 WO2006022954 A3 WO 2006022954A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzoureas
benzourea
diabetes
aryl
diabetic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/018721
Other languages
English (en)
Other versions
WO2006022954A2 (fr
Inventor
Weiguo Liu
Harold B Wood
Fiona Wai-Yu Lau-Phua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to EP05812065A priority Critical patent/EP1753423A4/fr
Priority to US11/597,817 priority patent/US20080076810A1/en
Priority to AU2005278099A priority patent/AU2005278099A1/en
Priority to JP2007515386A priority patent/JP2008501027A/ja
Priority to CA002565803A priority patent/CA2565803A1/fr
Publication of WO2006022954A2 publication Critical patent/WO2006022954A2/fr
Publication of WO2006022954A3 publication Critical patent/WO2006022954A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de benzo-urée de formule I possédant des substituants d'aryl-(CH2)x-oxazolidinédione ou d'aryl-(CH2)x-thiazolidinédione sur un des N atomes de l'anneau de benzo-urée, x étant égal à 0 ou 1. Lesdits composés sont des agonistes PPAR gamma ou des agonistes partiels et sont utilisés dans le traitement et la régulation de diabète de type II, notamment, de l'hyperglycémie et d'autres symptômes, tels que la dyslipidémie, l'hyperlipidémie, l'hypercholestérolémie, l'hypertriglycéridémie et l'obésité qui sont souvent associées au diabète de type II.
PCT/US2005/018721 2004-05-28 2005-05-26 Benzo-urees a activite antidiabetique Ceased WO2006022954A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05812065A EP1753423A4 (fr) 2004-05-28 2005-05-26 Benzo-urees a activite antidiabetique
US11/597,817 US20080076810A1 (en) 2004-05-28 2005-05-26 Benzoureas Having Anti-Diabetic Activity
AU2005278099A AU2005278099A1 (en) 2004-05-28 2005-05-26 Benzoureas having anti-diabetic activity
JP2007515386A JP2008501027A (ja) 2004-05-28 2005-05-26 抗糖尿病活性をもつベンゾ尿素
CA002565803A CA2565803A1 (fr) 2004-05-28 2005-05-26 Benzo-urees a activite antidiabetique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57514404P 2004-05-28 2004-05-28
US60/575,144 2004-05-28

Publications (2)

Publication Number Publication Date
WO2006022954A2 WO2006022954A2 (fr) 2006-03-02
WO2006022954A3 true WO2006022954A3 (fr) 2006-10-12

Family

ID=35967997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018721 Ceased WO2006022954A2 (fr) 2004-05-28 2005-05-26 Benzo-urees a activite antidiabetique

Country Status (6)

Country Link
EP (1) EP1753423A4 (fr)
JP (1) JP2008501027A (fr)
CN (1) CN101076334A (fr)
AU (1) AU2005278099A1 (fr)
CA (1) CA2565803A1 (fr)
WO (1) WO2006022954A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006014685A1 (de) 2006-03-28 2007-10-04 Sanofi-Aventis Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen
PT2100604E (pt) * 2008-03-10 2012-07-24 Nestec Sa Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas
RU2636483C2 (ru) * 2012-09-21 2017-11-23 Реоксин Дискавериз Груп, Инк. Ячейка для электролиза жидкости
JP7607799B2 (ja) * 2021-04-27 2024-12-27 メッドシャイン ディスカバリー インコーポレイテッド ６員芳香族ヘテロ尿素環の誘導体及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653478B2 (en) * 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
EP1546142A4 (fr) * 2002-08-29 2007-10-17 Merck & Co Inc Indoles presentant un effet antidiabetique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653478B2 (en) * 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1753423A4 *

Also Published As

Publication number Publication date
AU2005278099A1 (en) 2006-03-02
CN101076334A (zh) 2007-11-21
EP1753423A2 (fr) 2007-02-21
WO2006022954A2 (fr) 2006-03-02
JP2008501027A (ja) 2008-01-17
EP1753423A4 (fr) 2009-10-21
CA2565803A1 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2004066963A3 (fr) Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
WO2004019869A3 (fr) Indoles presentant un effet antidiabetique
EP1638947A4 (fr) Derives de triazole utiles comme inhibiteurs de la 11-beta hydroxysteroide deshydrogenase-1
JO2397B1 (en) Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU7705601A (en) N-substituted indoles useful in the treatment of diabetes
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
JO2315B1 (en) 11-pepta-hydroxy-sodium dehydrogenase inhibitors useful in the treatment of obesity, sugar, and dyslipidemia
CR9401A (es) Compuestos aromaticos condensados con actividad antidiabetica
CA2495943A1 (fr) Indoles a activite antidiabetique
IL159320A (en) Compounds for the treatment of metabolic disorders
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
WO2002060434A3 (fr) Derives d'acide benzopyranocarboxylique pour traiter le diabete et d'autres troubles lipidiques
NO20015607D0 (no) Glukagonantagonister/inversagonister
WO2006127503A3 (fr) Composes, compositions pharmaceutiques et methodes d'utilisation de ces derniers dans le traitement des troubles du metabolisme
EP1474139A4 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
WO2002026729A3 (fr) Derives d'acide benzopyrancarboxylique utilises pour le traitement du diabete et des troubles lipidiques
CY1106757T1 (el) Αντιδιαβητικες οξαζοδιδινοδιονες και θειαζολιδινοδιονες
WO2007009389A3 (fr) Derives de propanamide substitues, preparation et utilisation de ces derives
WO2006014262A3 (fr) Indoles a activite antidiabetique
WO2006022954A3 (fr) Benzo-urees a activite antidiabetique
WO2007018956A3 (fr) Oxazolidinediones et thiazolidinediones antidiabetiques
GEP20094854B (en) Compounds for treating diseases of impaired gastric motility
DE602005024384D1 (de) Neue verbindungen, ihre herstellung und verwendung
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
MY139550A (en) Indoles having anti-diabetic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2565803

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005278099

Country of ref document: AU

Ref document number: 6718/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11597817

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005812065

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580017194.5

Country of ref document: CN

Ref document number: 2007515386

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005278099

Country of ref document: AU

Date of ref document: 20050526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005278099

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005812065

Country of ref document: EP